PND22 Descriptive Analysis of the Direct Costs of Relapsing-Remitting Multiple Sclerosis in the Mexican Setting

Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.1946
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Cognitive Impairments in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis

Multiple Sclerosis
Neurology
2008English

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2009English

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2010English

Stressful Events Increase Exacerbations in Relapsing-Remitting Multiple Sclerosis

BMJ
2003English

PND14 Budgetary Impact of the Treatment of Relapsing-Remitting Multiple Sclerosis in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Cognitive Profile of Patients With Relapsing Remitting Multiple Sclerosis

Arquivos de Neuro-Psiquiatria
Biological PsychiatryNeurology
1999English

Intravenous Immunoglobulin G for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis

European Journal of Neurology
Neurology
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy